TY - JOUR
T1 - Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation
AU - Kim, Haein
AU - Merchant, Akil
AU - Darrah, Justin
AU - Sasine, Joshua
AU - Lee, Hannah
AU - Vescio, Robert
AU - Oveisi, David
AU - McGalliard, Brittany
AU - Linhares, Yuliya
AU - Rejali, Ali
AU - Van Strein, Patricia
AU - Klapper, Ellen
AU - Hekimian, Behrooz
AU - Chute, John
AU - Paquette, Ron
AU - Merin, Noah
N1 - Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2026/1/8
Y1 - 2026/1/8
N2 - BACKGROUND: Post-transplant cyclophosphamide (PTCy) was developed to allow the use of haploidentical donors for allogeneic stem cell transplantation (alloHSCT), then tested with matched donors. Cedars-Sinai Medical Center Blood and Marrow Transplant was an early adopter of PTCy for matched alloHSCT in 2016.PURPOSE OF THE RESEARCH: We retrospectively analyzed 15-year outcomes of patients who underwent alloHSCT with matched donor stem cells prior to 2016 (n = 252), with the outcomes of patients who were transplanted in the PTCy era, post-2016 (n = 99), to assess the impact of the switch to PTCy, while controlling for other differences between the cohorts.PRINCIPLE RESULTS: Overall Survival (OS) was better in the PTCy group (at 1 year, 90% vs 62%, P < .0001), and the difference persisted in OS at 2 years and 3 years. There was no difference in relapse (26% non-PTCy vs 19% PTCy; P = .3560). Non-relapse mortality was lower with PTCy, 7% vs 22% without, P = .0002. Acute GVHD was lower in the PTCy group (16% PTCy vs 33% non-PTCy, P = .0013). Chronic GVHD was similar between the two groups, 35% in the PTCy group and 42% in the non-PTCy group (P = .1235), but the rate of extensive cGVHD was lower, 15% with PTCy vs 29% without; P = .0078. Post-transplant hospital stay was shorter, 23 ± 13.1 days in the non-PTCy group and 18 ± 7.0 days with PTCy, P < .0001.CONCLUSIONS: Long-term follow up of patients transplanted using PTCy with matched donors has demonstrated superiority of PTCy compared to tacrolimus methotrexate.
AB - BACKGROUND: Post-transplant cyclophosphamide (PTCy) was developed to allow the use of haploidentical donors for allogeneic stem cell transplantation (alloHSCT), then tested with matched donors. Cedars-Sinai Medical Center Blood and Marrow Transplant was an early adopter of PTCy for matched alloHSCT in 2016.PURPOSE OF THE RESEARCH: We retrospectively analyzed 15-year outcomes of patients who underwent alloHSCT with matched donor stem cells prior to 2016 (n = 252), with the outcomes of patients who were transplanted in the PTCy era, post-2016 (n = 99), to assess the impact of the switch to PTCy, while controlling for other differences between the cohorts.PRINCIPLE RESULTS: Overall Survival (OS) was better in the PTCy group (at 1 year, 90% vs 62%, P < .0001), and the difference persisted in OS at 2 years and 3 years. There was no difference in relapse (26% non-PTCy vs 19% PTCy; P = .3560). Non-relapse mortality was lower with PTCy, 7% vs 22% without, P = .0002. Acute GVHD was lower in the PTCy group (16% PTCy vs 33% non-PTCy, P = .0013). Chronic GVHD was similar between the two groups, 35% in the PTCy group and 42% in the non-PTCy group (P = .1235), but the rate of extensive cGVHD was lower, 15% with PTCy vs 29% without; P = .0078. Post-transplant hospital stay was shorter, 23 ± 13.1 days in the non-PTCy group and 18 ± 7.0 days with PTCy, P < .0001.CONCLUSIONS: Long-term follow up of patients transplanted using PTCy with matched donors has demonstrated superiority of PTCy compared to tacrolimus methotrexate.
U2 - 10.1016/j.transproceed.2025.12.008
DO - 10.1016/j.transproceed.2025.12.008
M3 - Article
C2 - 41513527
SN - 0041-1345
JO - Transplantation proceedings
JF - Transplantation proceedings
ER -